Why Stoke Therapeutics, Inc.’s (STOK) Stock Is Down 6.73%
As of Tuesday, October 06, Stoke Therapeutics, Inc.’s STOK share price has dipped by 6.73%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Commentary & Analysis
Why Stoke Therapeutics, Inc.’s (STOK) Stock Is Down 5.80%
As of Wednesday, September 23, Stoke Therapeutics, Inc.’s STOK share price has dipped by 5.80%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Stoke Therapeutics, Inc.’s (STOK) Stock Is Down 5.37%
As of Tuesday, September 15, Stoke Therapeutics, Inc.’s STOK share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Is Stoke Therapeutics, Inc. (STOK) Overvalued?
We dive into why Stoke Therapeutics, Inc. (STOK) could be considered overvalued on 2026-08-05, based on AAII’s Value Score and Grade.Jenna Brashear
What You Need to Know About Stoke Therapeutics, Inc.'s Q3 Earnings
Stoke Therapeutics, Inc.'s fiscal Q3 earnings report was released on Monday, August 03. Let's dive in to see if (STOK) missed or beat analyst's expectations.Michael Rose
Financial Summary
| Share Statistics | STOK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,559.6 | $208.8 | 51% |
|
| Shares Out (Mil) | 66.0 | 53.9 | 54% |
|
| Institutional Ownership | 96.3% | 93.1% | 69% |
|
| Float (Mil) | 45.6 | 41.4 | 45% |
|
| Beta | 1.23 | 0.95 | 72% |
|
| Avg Daily Volume (000s) | 812 | 614 | 66% |
|
| Price Change (52-week) |
(32.1%) | 45.3% | 29% |
|
| Growth | STOK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | 33.3% | (10.2%) | 87% |
|
| EPS (5yr) | 40.5% | 15.7% | 89 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.0%) | (15.7%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 12 | |
| Current EPS | ($0.914) | ($3.621) | ($3.528) | |
| Month Ago EPS | ($0.914) | ($3.621) | ($3.515) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 4 | 0 | 0 | |
| Three Months Ago EPS | ($0.826) | ($3.295) | ($3.090) | |
| Year/Year Chg | (2.0%) | 3,022% | 1,972% | |
| Financials | STOK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $28 | $37 | 15% |
|
| Net Income (TTM) (Mil) | ($208) | ($44) | 6% |
|
| EPS (TTM) | ($3.330) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($178) | ($33) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $2 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $1,483 | $174 | 45% |
|
| Valuation | STOK | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.36 | 2.09 | 77% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | STOK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.0% | 96% |
|
| Net Margin | (753.6%) | (75.3%) | 1% |
|
| ROA | (53.4%) | (47.2%) | 11% |
|
| ROE | (61.1%) | (54.2%) | 13% |
|
| Liabilities to Assets | 12.3% | 29.1% | 7% |
|
| F-Score | 3 | 2 | 18% |
|
Stoke Therapeutics, Inc. did not pass any screens on 10/16/2026.
